Financial StabilityDogwood announced that its largest shareholder, CK Life Sciences, through its wholly-owned subsidiary, Conjoint Inc, exchanged the $19.5M loan agreement (+ interest) with Dogwood to preferred stock. This is a significant positive for Dogwood as it further demonstrates CKLS' commitment to the development of Halneuron (Nav1.7) for pain.
Market OpportunityAnalyst's recommendation is upgraded to Buy based on a positive outlook on the upcoming interim results and the market opportunity for Halneuron.
Regulatory ApprovalThe company has received FDA special protocol assessment approval to conduct a Phase 3 registration-directed study of Halneuron in the U.S., Canada, and E.U.